Key result
Bariatric surgery improves CV risk biomarkers including total cholesterol and triglycerides in T2D.
Why the study?
While bariatric surgery offers metabolic benefits in obesity-related T2D, long-term durability and remission vary, prompting exploration of omics modalities to reveal CVD-linked biomarkers.
Does bariatric surgery improve omics-based cardiovascular and inflammatory biomarkers in patients with type 2 diabetes?
Meta-Analysis
Does bariatric surgery improve omics-based cardiovascular and inflammatory biomarkers in patients with type 2 diabetes?
Effect estimate: MD 0.44 (95% CI 0.06-0.82)
p-value: p=0.02
Bariatric surgery in patients with type 2 diabetes significantly improves multiple omics-derived cardiovascular and inflammatory biomarkers, supporting its role in reducing cardiovascular risk.
Supports bariatric surgery for CV risk reduction in T2D; confirms lipid biomarker improvements in meta-analysis.
Type 2 diabetes (T2D) is a complex, multifactorial metabolic disorder, and while bariatric surgery has emerged as a promising intervention for obesity-related T2D with significant metabolic benefits, its long-term durability and potential for remission vary among patients. This systematic review and meta-analysis explore how omics modalities-such as genomics, epigenomics, transcriptomics, metabolomics, proteomics, and gut microbiome-can reveal potential biomarkers linked to cardiovascular disease (CVD) of T2D patients who undergo bariatric surgery. Following PRISMA 2020 guidelines, a systematic search in PubMed identified 49 eligible studies. The meta-analysis of eight proteomic biomarkers, showed significant post-surgery improvements in total cholesterol (mean difference (MD) 0.44 (95% CI: 0.06-0.82), p = 0.02), triglycerides (MD 1.00 (0.77-1.24), p < 0.00001), LDL cholesterol (MD 0.27 (0.02, 0.52), p = 0.03), HDL cholesterol (MD -0.22 (-0.30, -0.15), p < 0.00001), hsCRP (MD 0.64 (0.44, 0.84), p < 0.00001), C peptide levels (MD 1.29 (0.96, 1.61), p < 0.0001), and IL-6 (MD 1.84 (0.85, 2.84), p = 0.0003). These findings highlight the value of integrated omics in developing personalized diagnostics, predicting disease risks, and designing targeted therapies. The present study is the first systematic review presenting the omics disciplines that offer a comprehensive view of the effectiveness of bariatric surgery in managing T2D, subsequently reducing the risk of CVD.
No takes yet. Share an insight, caveat, or question.
Almazrouei et al. (2025) conducted a meta-analysis in Type 2 diabetes. Bariatric surgery vs. Pre-surgery baseline was evaluated on Total cholesterol (MD 0.44, 95% CI 0.06-0.82, p=0.02). Bariatric surgery significantly improved cardiovascular risk biomarkers in patients with type 2 diabetes, including reductions in total cholesterol (MD 0.44) and triglycerides (MD 1.00).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: